WO2008114501A1 - 癌の診断薬及び治療薬 - Google Patents

癌の診断薬及び治療薬 Download PDF

Info

Publication number
WO2008114501A1
WO2008114501A1 PCT/JP2008/000586 JP2008000586W WO2008114501A1 WO 2008114501 A1 WO2008114501 A1 WO 2008114501A1 JP 2008000586 W JP2008000586 W JP 2008000586W WO 2008114501 A1 WO2008114501 A1 WO 2008114501A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
cancer
diagnostic
therapeutic agent
therapeutic
Prior art date
Application number
PCT/JP2008/000586
Other languages
English (en)
French (fr)
Inventor
Hiroyuki Aburatani
Takao Hamakubo
Isao Kohno
Original Assignee
Perseus Proteomics Inc.
The University Of Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perseus Proteomics Inc., The University Of Tokyo filed Critical Perseus Proteomics Inc.
Publication of WO2008114501A1 publication Critical patent/WO2008114501A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

　癌を診断および治療する新規方法を提供すること。 　抗ＨＮＴ抗体を含有する癌の診断薬および治療薬。
PCT/JP2008/000586 2007-03-16 2008-03-14 癌の診断薬及び治療薬 WO2008114501A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-068053 2007-03-16
JP2007068053A JP2010133705A (ja) 2007-03-16 2007-03-16 癌の診断薬及び治療薬

Publications (1)

Publication Number Publication Date
WO2008114501A1 true WO2008114501A1 (ja) 2008-09-25

Family

ID=39765620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/000586 WO2008114501A1 (ja) 2007-03-16 2008-03-14 癌の診断薬及び治療薬

Country Status (2)

Country Link
JP (1) JP2010133705A (ja)
WO (1) WO2008114501A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5794511B2 (ja) * 2010-08-31 2015-10-14 国立大学法人 東京大学 オートタキシン測定による膵疾患の検査方法および検査薬
WO2024024565A1 (ja) * 2022-07-28 2024-02-01 国立大学法人 東京大学 ニューロトリミンの機能阻害剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004535806A (ja) * 2001-06-27 2004-12-02 キャンサー・リサーチ・テクノロジー・リミテッド 癌
DE102004042822A1 (de) * 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
JP2006136323A (ja) * 1998-03-10 2006-06-01 Genentech Inc 新規なポリペプチド及びそれをコードする核酸

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006136323A (ja) * 1998-03-10 2006-06-01 Genentech Inc 新規なポリペプチド及びそれをコードする核酸
JP2004535806A (ja) * 2001-06-27 2004-12-02 キャンサー・リサーチ・テクノロジー・リミテッド 癌
DE102004042822A1 (de) * 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EVANGELOS NTOUGKOS ET AL.: "The IgLON family in epithelial ovarian cancer: expression profiles and clinicopathologic correlates", HUMAN CANCER BIOLOGY, vol. 11, no. 16, 15 August 2005 (2005-08-15), pages 5764 - 5768, XP003027705, DOI: doi:10.1158/1078-0432.CCR-04-2388 *
ORLANDO D. GIL ET AL.: "Complementary expression and heterophilic interactions between IgLON family members Neurotrimin and LAMP", NEUROTRIMIN AND LAMP, J. NEUROBIOL., vol. 51, no. 3, 2002, pages 190 - 204 *

Also Published As

Publication number Publication date
JP2010133705A (ja) 2010-06-17

Similar Documents

Publication Publication Date Title
WO2008153705A3 (en) Methods of treating, diagnosing and detecting fgf21-associated disorders
WO2010017515A3 (en) Breast cancer specific markers and methods of use
EP2103628A4 (en) MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2006011810A3 (en) Mr imaging method for the discrimination between healthy and tumour tissue
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2006085906A3 (en) Method for the direct detection of diagnostic rna
EP1922326A4 (en) BIOMARKERS USEFUL FOR DIAGNOSING PROSTATE CANCER AND METHOD OF USE THEREOF
WO2007135546A3 (en) TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES
WO2010025414A3 (en) Diagnostics and treatments for vegf-independent tumors
WO2007047408A3 (en) Promac signature application
WO2007118214A3 (en) Antibody compositions and methods for treatment of neoplastic disease
WO2007115045A3 (en) Diagnostics and treatments for tumors
WO2009083009A3 (en) Monoclonal antibodies against cd32b
PT1949285T (pt) Sistemas e métodos para tratamento, diagnóstico e previsão da ocorrência de uma condição médica
IL191538A0 (en) Method for diagnosing, prognosing and treating glioma
EP1742654A4 (en) ANTI-LFL2 ANTIBODIES FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER
WO2011015333A3 (en) Targeting of bone marrow neovasculature
WO2007053284A3 (en) Method of treating breast cancer using 17-aag or 17-ag or a prodrug of either in combination with a her2 inhibitor
EP2564864B8 (en) FGF2-related methods for diagnosing and treating depression
WO2007123722A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2010009171A3 (en) Src activation for determining cancer prognosis and as a target for cancer therapy
WO2007092444A3 (en) Method and apparatus for dynamically correlating neurological and cardiovascular parameters and for diagnosing and treating patients using the same
WO2010054377A3 (en) Fully human antibodies against n-cadherin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08720472

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08720472

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP